Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $14.31 Analyst target: $20.20 Upside: 41.11%
Korro Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases. The company is headquartered in Cambridge, Massachusetts.
See the full interactive analysis & chart →Informational only — not investment advice.